Susquehanna International Group
ANTX icon

Susquehanna International Group’s AN2 Therapeutics ANTX Stock Holding History

Susquehanna International Group’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-22,240
Closed -$25.4K – 13106
2025
Q4 		$25.4K Buy
+22,240
New +$26K ﹤0.01% 11915
2025
Q3 		– Sell
-45,320
Closed -$48K – 12302
2025
Q2 		$48K Buy
+45,320
New +$54K ﹤0.01% 12126
2024
Q3 		– Sell
-31,245
Closed -$67.2K – 11891
2024
Q2 		$67.2K Sell
31,245
-171,605
-85% -$408K ﹤0.01% 11270
2024
Q1 		$659K Buy
202,850
+103,446
+104% +$1.13M ﹤0.01% 7842
2023
Q4 		$2.04M Buy
99,404
+75,141
+310% +$1.26M ﹤0.01% 5306
2023
Q3 		$390K Buy
+24,263
New +$275K ﹤0.01% 8798
2022
Q4 		– Sell
-16,827
Closed -$292K – 12325
2022
Q3 		$292K Sell
16,827
-10,192
-38% -$119K ﹤0.01% 9857
2022
Q2 		$209K Buy
+27,019
New +$358K ﹤0.01% 10520

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Susquehanna International Group's ANTX Position: Q1 2026 in Review

Susquehanna International Group sold out of AN2 Therapeutics (ANTX) in Q1 2026, closing a stake of 22,240 shares — an estimated $25.4K sold.

Susquehanna International Group first reported a position in ANTX in Q2 2022 and held it in 8 quarters. The position peaked at $2.04M in Q4 2023. 52 funds tracked by Wall St. Rank hold ANTX as of Q1 2026.

  • Susquehanna International Group reported no remaining AN2 Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Susquehanna International Group sold 22,240 AN2 Therapeutics shares in Q1 2026, an estimated $25.4K.
  • Susquehanna International Group first reported a position in AN2 Therapeutics in Q2 2022 and held it in 8 quarters.
  • Susquehanna International Group's AN2 Therapeutics position peaked at $2.04M in Q4 2023.
  • 52 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.